ArticleBioorganic & medicinal chemistry2026
Design, synthesis, and biological evaluation of a focused pyrrolo- and pyrido-quinazolinone natural products-templated library for anti-fungal and anthelmintic activities.
Article in Bioorganic & medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A focused pyrrolo- and pyrido-quinazoline natural products-templated library has been designed and synthesized using two novel synthetic approaches: an aza-Nazarov approach and a Dieckmann cyclization strategy. This privileged scaffold-based collection was screened against pathogenic fungi and parasitic helminths. Three compounds (23b, 25a, 13f) emerged as potent inhibitors of Candida auris adhesion, each causing more than 50 % inhibition at 10 μM, and two compounds (13k, 14h) displayed strong anthelmintic activity, demonstrating 7- to 28-fold enhanced activity against human hookworms relative to albendazole. These molecules represent promising leads for the design and synthesis of focused quinazolinone analogs to support SAR driven optimization against C. auris or helminth pathogens. Ongoing efforts aim to refine these bioactive leads by improving their pharmacokinetic and activity profiles through targeted structural modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.